Cytokinetics (CYTK) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $61.13 -1.89%
Revenue Growth %: +2,004.1%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +2,004.1%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Intel shares fall as competitor reports record results
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
